APSR2026-728

Yes
Late-Breaking
Submitted
Oral Presentation
AO18-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1221169-46903-Chiew Siow Yeh (APSR A018-005)_439786.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

SIOW YEH CHIEW * MINISTRY OF HEALTH KLINIK KESIHATAN BANDAR KUANTAN KUANTAN Malaysia
SIEW CHIN ONG - UNIVERSITI SAINS MALAYSIA SCHOOL OF PHARMACEUTICAL SCIENCES MINDEN Malaysia
MUSTAPHA MOHAMMED - QATAR UNIVERSITY BIOMEDICAL RESEARCH CENTER, QU HEALTH DOHA Qatar
SYAZATUL SYAKIRIN SIROL AFLAH - MINISTRY OF HEALTH INSTITUT PERUBATAN RESPIRATORI KUALA LUMPUR Malaysia
NOORUL AFIDZA MUHAMMAD - MINISTRY OF HEALTH HOSPITAL SULTAN IDRIS SHAH SERDANG SERDANG Malaysia
IRFHAN ALI HYDER ALI - MINISTRY OF HEALTH HOSPITAL PULAU PINANG GEORGE TOWN Malaysia
SZE SHYANG KHO - MINISTRY OF HEALTH HOSPITAL UMUM SARAWAK KUCHING Malaysia
SHEREEN SUYIN CH’NG - MINISTRY OF HEALTH HOSPITAL SELAYANG SELAYANG Malaysia
 
 
 
 
 
 
 
Presenting Author Details
SIOW YEH
CHIEW
chiewsiowyeh@moh.gov.my
+60176911138
31-40
Malaysia
Original Research
Treatment Patterns, Antifibrotic Use, and Direct Medical Costs in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Real-World Evidence from Malaysia
Maximum 25 words
Abstract Content
Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) share similar clinical behaviour, with substantial clinical and economic burden. Antifibrotic therapy has become the mainstay of IPF management, with increasing evidence supporting its use in PPF. However, real-world treatment patterns and economic implications remain understudied in Malaysia. This study aimed to evaluate treatment patterns, antifibrotic use, and direct medical costs associated with IPF and PPF management in Malaysia.
A retrospective multicenter study was conducted among IPF and PPF patients treated at five government hospitals in Malaysia between January 2018 and September 2023. Medical records were reviewed over a one-year follow-up period from diagnosis to obtain treatment information and healthcare resource utilization. Annual direct medical costs were estimated from the healthcare provider’s perspective.
65 IPF and 79 PPF patients were identified. Antifibrotics were the main treatment among IPF patients, with 83.1% receiving antifibrotic therapy. In contrast, immunosuppressants and corticosteroids were more commonly prescribed among PPF, particularly those with autoimmune-related ILD, with only 49.4% receiving antifibrotics. Incidence of adverse drug reactions was 44% for Nintedanib and 50% for Pirfenidone, resulting in treatment discontinuation rates of 9.1% and 18.8%, respectively. The mean annual direct cost was $4,100 (±$3,690) per IPF patient and $3,998 (±$4,310) per PPF patient. Outpatient care contributed 74%, and total costs were driven mainly by medications (69%). Regression analysis identified antifibrotic therapy, hospitalisations, and acute exacerbations as predictors of increasing annual costs.
This study highlights real-world treatment patterns and the substantial economic burden associated with IPF and PPF in Malaysia. Effective antifibrotic treatments that delay disease progression and prevent exacerbations may optimise clinical outcomes while mitigating downstream hospitalisation and exacerbation costs within the public healthcare system.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
interstitial lung disease, treatment pattern, direct medical costs
maximum 3 keywords and no abbreviations, separated by commas
Acknowledgements We would like to thank the Director General of Health Malaysia for his permission to present this article. We also acknowledge the contribution of data collectors from participating hospitals. Disclosure Statement The study was supported and funded by Boehringer Ingelheim. The authors did not receive payment related to the development of this study. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Individual disclosures: Siew Chin Ong has received research funding for research projects from Boehringer Ingelheim and AstraZeneca. Syazatul Syakrin has received consulting fees for an ILD advisory board from Boehringer Ingelheim. Sze Shyang Kho has received lecture honoraria from Boehringer Ingelheim. Irfhan Ali has received lecture honoraria from Boehringer Ingelheim, AstraZeneca, GSK, Novartis, Menarini, Hetero, Sanofi, and Pfizer. Shereen Suyin has received advisory fees from Boehringer Ingelheim, Pfizer, Novartis, Johnson & Johnson, AstraZeneca, and GSK. All other authors declare that they have no competing interests.
284